ADCT ADC TherapeuticsWatchlist
About ADC Therapeutics Company
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Analyst Expectations for ADC Therapeutics's Future
Within the last quarter, ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings22000Last 30D100001M Ago010002M
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $3
HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $12 to $3.
Sobi to Present New Data at ASH 2023 Annual Meeting
Sobi will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December...